Advances in the Synthesis of GABAergic Modulators for Anxiety and Depression: Pathways and Potential Applications

Anxiety and depression are among the most common and debilitating neuropsychiatric disorders worldwide. The shortcomings of existing treatments, including delayed onset, partial response, and unfavorable side effects, underscore the pressing need for more efficient and focused treatments. The brain's main inhibitory network, the GABAergic system, is increasingly being shown to be a crucial modulator of emotional and cognitive control. This study provides a comprehensive analysis of GABAergic modulators across pharmacological, molecular, and clinical domains in treating anxiety and depression. In contrast to past reviews, we investigate how GABA-A receptor subtypes differ in their involvement in anxiety disorders and depression subtypes (such as major depressive disorder, treatment-resistant depression, and postpartum depression), establishing links between receptor-selective pharmacology and symptom-specific treatment outcomes. We review current and post-2021 clinical studies and discuss recent developments in the synthesis of subtype- selective modulators, the function of neurosteroids, and the importance of extrasynaptic GABAergic transmission. The study also emphasizes how receptor mapping and structure-activity correlations influence the development of next-generation drugs. We propose that the development of subtype-selective GABA-A receptor modulators represents a pivotal advancement in addressing the limitations of conventional therapies, particularly their dependence, sedation, and delayed onset. By integrating medicinal chemistry with clinical neuropharmacology, this review highlights how targeting specific receptor subtypes opens the door to safer, faster-acting, and more durable treatments for anxiety and depression.